<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370422</url>
  </required_header>
  <id_info>
    <org_study_id>8412</org_study_id>
    <nct_id>NCT00370422</nct_id>
  </id_info>
  <brief_title>Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of intravitreal injection of
      bevacizumab alone versus bevacizumab combined with triamcinolone for treatment of refractory
      diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the early treatment diabetic retinopathy study (ETDRS), the treatment of choice
      for diabetic macular edema is laser therapy, which may be neither effective nor curative in
      some patients. Corticosteroids may have a beneficial effect on diabetic macular edema. Other
      newly introduced medications for macular edematous lesions are anti-VEGF vascular endothelial
      growth factor)drugs. In this randomized, sham-controlled, multicenter, three-arm clinical
      trial,we try to evaluate the safety and efficacy of intravitreal bevacizumab alone and in
      combination with intravitreal triamcinolone in the treatment of refractory diabetic macular
      edema.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Central macular thickness</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cataract progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber reaction</measure>
  </secondary_outcome>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone, Bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases with clinically significant macular edema (CSME) with persistent retinal
             thickening after initial or supplemental macular photocoagulation

        Exclusion Criteria:

          -  Monocularity,

          -  History of vitrectomy,

          -  Glaucoma or ocular hypertension,

          -  Significant media opacity,

          -  Existence of traction on the macula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamid Ahmadieh, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>March 12, 2007</last_update_submitted>
  <last_update_submitted_qc>March 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2007</last_update_posted>
  <keyword>Cystoid macular edema</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Hard exudates</keyword>
  <keyword>Intravitreal bevacizumab</keyword>
  <keyword>Intravitreal triamcinolone</keyword>
  <keyword>Macular thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

